A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells
1
Issued Date
2023-02-24
Resource Type
ISSN
0264410X
eISSN
18732518
Scopus ID
2-s2.0-85147388632
Pubmed ID
36740559
Journal Title
Vaccine
Volume
41
Issue
9
Start Page
1638
End Page
1648
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine Vol.41 No.9 (2023) , 1638-1648
Suggested Citation
Seesen M., Jearanaiwitayakul T., Limthongkul J., Midoeng P., Sunintaboon P., Ubol S. A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells. Vaccine Vol.41 No.9 (2023) , 1638-1648. 1648. doi:10.1016/j.vaccine.2023.01.062 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/81580
Title
A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells
Author's Affiliation
Other Contributor(s)
Abstract
Dengue is the most prevalent mosquito-borne viral disease and continues to be a global public health concern. Although a licensed dengue vaccine is available, its efficacy and safety profile are not satisfactory. Hence, there remains a need for a safe and effective dengue vaccine. We are currently developing a bivalent dengue vaccine candidate. This vaccine candidate is composed of a C-terminus truncated non-structural protein 1 (NS11-279) and envelope domain III (EDIII) of DENV-2 encapsidated in the nanocarriers, N, N, N-trimethyl chitosan nanoparticles (TMC NPs). The immunogenicity of this bivalent vaccine candidate was investigated in the present study using BALB/c mice. In this work, we demonstrate that NS1 + EDIII TMC NP-immunized mice strongly elicited antigen-specific antibody responses (anti-NS1 and anti-EDIII IgG) and T-cell responses (NS1- and EDIII-specific-CD4+ and CD8+ T cells). Importantly, the antibody response induced by NS1 + EDIII TMC NPs provided antiviral activities against DENV-2, including serotype-specific neutralization and antibody-mediated complement-dependent cytotoxicity. Moreover, the significant upregulation of Th1- and Th2-associated cytokines, as well as the increased levels of antigen-specific IgG2a and IgG1, indicated a balanced Th1/Th2 response. Collectively, our findings suggest that NS1 + EDIII TMC NPs induced protective responses that can not only neutralize infectious DENV-2 but also eliminate DENV-2-infected cells.